Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1194/jlr.M800539-JLR200 on February 18, 2009

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M800539-JLR200v1
50/8/1538    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Navab, M.
Right arrow Articles by Fogelman, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navab, M.
Right arrow Articles by Fogelman, A. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 50, 1538-1547, August 2009
Copyright © 2009 by American Society for Biochemistry and Molecular Biology

A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids

Mohamad Navab1,*, Piotr Ruchala*, Alan J. Waring*, Robert I. Lehrer*, Susan Hama*, Greg Hough*, Mayakonda N. Palgunachari{dagger}, G. M. Anantharamaiah{dagger} and Alan M. Fogelman*

* Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095-1679; Atherosclerosis Research Unit
{dagger} Department of Medicine, University of Alabama, Birmingham, AL 35294

1 To whom correspondence should be addressed. e-mail: mnavab{at}mednet.ucla.edu

Administered subcutaneously, D-4F or L-4F are equally efficacious, but only D-4F is orally efficacious because of digestion of L-4F by gut proteases. Orally administering niclosamide (a chlorinated salicylanilide used as a molluscicide, antihelminthic, and lampricide) in temporal proximity to oral L-4F (but not niclosamide alone) in apoE null mice resulted in significant improvement (P < 0.001) in the HDL-inflammatory index (HII), which measures the ability of HDL to inhibit LDL-induced monocyte chemotactic activity in endothelial cell cultures. Oral administration of L-[113-122]apoJ with niclosamide also resulted in significant improvement (P < 0.001) in HII. Oral administration of niclosamide and L-4F together with pravastatin to female apoE null mice at 9.5 months of age for six months significantly reduced aortic sinus lesion area (P = 0.02), en face lesion area (P = 0.033), and macrophage lesion area (P = 0.02) compared with pretreatment, indicating lesion regression. In contrast, lesions were significantly larger in mice receiving only niclosamide and pravastatin or L-4F and pravastatin (P < 0.001). In vitro niclosamide and L-4F tightly associated rendering the peptide resistant to trypsin digestion. Niclosamide itself did not inhibit trypsin activity. The combination of niclosamide with apolipoprotein mimetic peptides appears to be a promising method for oral delivery of these peptides.—Navab, M. P., Ruchala, A. J. Waring, R. I. Lehrer, S. Hama, G. Hough, M. N. Palgunachari, G. M. Anantharamaiah, and A. M. Fogelman. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J. Lipid Res. 2009. 50: 1538–1547.

Supplementary key words atherosclerosis • apolipoprotein A-I • apolipoprotein A-I mimetic peptides • lipoproteins • HDL

Abbreviations: apoA-I, apolipoprotein A-I; HII, HDL-inflammatory index; LPS, bacterial lipopolysaccaride; TFA, trifluroacetic acid; FTIR, Fourier transform infrared; ATR, attenuated total reflectance


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
M. Navab, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman
HDL as a Biomarker, Potential Therapeutic Target, and Therapy
Diabetes, December 1, 2009; 58(12): 2711 - 2717.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
A. N. Hoofnagle and J. W. Heinecke
Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins
J. Lipid Res., October 1, 2009; 50(10): 1967 - 1975.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2009 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement